Foundayo Does Not Cause Basophilia, Eosinophilia, or Macrocytosis
Based on the FDA-approved drug label for Foundayo (orforglipron), there is no evidence that this medication causes basophilia, eosinophilia, or macrocytosis. 1
What the Evidence Shows
Foundayo's Adverse Event Profile
The FDA label for Foundayo clearly lists all adverse reactions occurring in ≥5% of treated patients: nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, and hair loss. 1 Notably absent from this comprehensive list are any hematologic abnormalities including basophilia, eosinophilia, or macrocytosis.
Hematologic Effects of GLP-1 Receptor Agonists
While one guideline mentions that "post treatment lymphocytosis, eosinophilia, neutrophilia and monocytosis can be observed" with immune checkpoint inhibitors (ICIs), this refers to a completely different drug class and mechanism 2. Foundayo is a GLP-1 receptor agonist, not an immune checkpoint inhibitor, and operates through an entirely different pharmacologic pathway.
Understanding These Blood Abnormalities
If you're seeing these findings in a patient taking Foundayo, you need to look elsewhere for the cause:
Eosinophilia Causes to Consider
- Allergic disorders (most common, ~80% of cases): asthma, food allergies, atopic dermatitis, drug reactions 3
- Parasitic infections (second most common): particularly Strongyloides stercoralis 3, 4
- Myeloid neoplasms: including those with PDGFRA, PDGFRB, or FGFR1 rearrangements 3, 5
- Lymphoid malignancies: especially T-cell lymphomas 3
- Hypereosinophilic syndromes: defined as AEC >1500 cells/μL with end-organ damage 6
Basophilia Causes to Consider
- Myeloproliferative neoplasms: particularly chronic myeloid leukemia, polycythemia vera, essential thrombocythemia 7, 8
- Myelodysplastic syndromes: basophilia occurs in 4.09% of MDS cases and correlates with ASXL1 and U2AF1 mutations 9, 7
- Systemic mastocytosis: especially SM with associated hematologic neoplasm 10
Macrocytosis Causes to Consider
- Vitamin B12 or folate deficiency: most common megaloblastic cause 11
- Myelodysplastic syndromes: non-megaloblastic macrocytosis 11
- Medications: hydroxyurea, diphenytoin 11
- Alcoholism: non-megaloblastic 11
Clinical Pitfall to Avoid
Do not attribute new hematologic abnormalities to Foundayo without a thorough workup. The drug's safety profile is well-characterized, and these findings are not part of it. Missing an underlying myeloid neoplasm, parasitic infection, or vitamin deficiency because you assumed the medication was responsible could lead to significant patient harm.
If your patient on Foundayo develops any of these blood count abnormalities, proceed with standard diagnostic evaluation including peripheral smear review, reticulocyte count, vitamin B12/folate levels, and consideration of bone marrow biopsy with cytogenetics and molecular testing if a primary hematologic disorder is suspected 3, 11.